Home › Diffuse Intrinsic Pontine Glioma › Washington
Diffuse Intrinsic Pontine Glioma clinical trials in Washington
10 studies for Diffuse Intrinsic Pontine Glioma are looking for participants at sites in Washington.
Cities in Washington
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Sep 21, 2026 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Seattle Children's Hospital, Seattle
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Aug 4, 2026 · NCT07680439Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Seattle Children's Hospital, Seattle
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Combination Therapy for the Treatment of Diffuse Midline Gliomas
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 2 to 39 · All sexes · Updated Jun 26, 2026 · NCT05009992Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
- Seattle Children's Hospital, Seattle
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Seattle Children's Hospital, Seattle
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.